Relative systemic hypertension in patients with sickle cell disease is associated with risk of pulmonary hypertension and renal insufficiency.
We analyzed entry data from 163 adult hemoglobin SS and Sbeta(0) thalassemia patients enrolled in the prospective Sickle Cell Pulmonary Hypertension Screening Study and stratified their ECHO-determined tricuspid regurgitant jet velocity (TRV) and serum creatinine concentration according to three systemic blood pressure categories. TRV was >or= 2.5 m/sec in 27% of the patients with systolic blood pressure (SBP) <120 mmHg and diastolic blood pressure (DBP) <70 mmHg, in 37% with SBP 120-139 mmHg or DBP 70-89 mmHg, and in 93% with SBP 140 mmHg or DBP 90 mmHg or higher (P<0.0005 for trend). Serum creatinine concentration was 1.0 mg/dL or higher in 7% of patients with SBP <120 mmHg and DBP <70 mmHg, in 17% with SBP 120-139 mmHg or DBP 70-89 mmHg and 50% with SBP 140 mmHg or DBP 90 mmHg or higher (P<0.0005 for trend). Over 2 years of follow-up, there were trends for more frequent progression to elevated TRV (P=0.073) or creatinine (P=0.037) values according to the higher systemic blood pressure categories. Our findings suggest that systemic SBP 120-139 mmHg or DBP 70-89 mmHg defines a category of relative systemic hypertension in patients with sickle cell disease that is associated with increased risk for pulmonary hypertension and renal dysfunction. Whether antihypertensive and/or nitric oxide donor therapy in sickle cell disease patients with relative hypertension prevents these and other complications should be determined by clinical trials.
Gordeuk
Victor R
VR
Center for Sickle Cell Disease, Howard University, Washington, District of Columbia 20060, USA. vgordeuk@howard.edu
Sachdev
Vandana
V
Taylor
James G
JG
Gladwin
Mark T
MT
Kato
Gregory
G
Castro
Oswaldo L
OL
D000328:Adult; D000755:Anemia, Sickle Cell / Q000097:blood / Q000150:complications* / Q000503:physiopathology; D003401:Creatine / Q000097:blood; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000150:complications* / Q000503:physiopathology; D006976:Hypertension, Pulmonary / Q000097:blood / Q000150:complications* / Q000503:physiopathology; D007674:Kidney Diseases / Q000097:blood / Q000150:complications* / Q000503:physiopathology; D008297:Male; D012307:Risk Factors
D003401:Creatine
Am J Hematol. 2003 Oct;74(2):104-11
14508796
Hypertension. 2004 Dec;44(6):924-9
15534075
JAMA. 2005 Jul 6;294(1):81-90
15998894
Blood. 2006 Mar 15;107(6):2279-85
16291595
Am J Hematol. 2006 Jul;81(7):503-10
16755569
Br J Haematol. 2006 Jul;134(1):109-15
16803576
J Am Soc Nephrol. 2006 Aug;17(8):2228-35
16837635
Blood Rev. 2007 Jan;21(1):37-47
17084951
J Am Coll Cardiol. 2007 Jan 30;49(4):472-9
17258093
Am J Respir Crit Care Med. 2007 Jun 15;175(12):1272-9
17379852
Am J Physiol Heart Circ Physiol. 2000 Jun;278(6):H1799-806
10843875
South Med J. 2000 Jun;93(6):590-2
10881775
Am J Physiol Regul Integr Comp Physiol. 2000 Dec;279(6):R1949-55
11080057
Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15215-20
11752464
Nat Med. 2002 Dec;8(12):1383-9
12426562
Circulation. 2003 Jan 21;107(2):271-8
12538427
Blood. 2003 Feb 15;101(4):1257-61
12393669
Curr Opin Hematol. 2003 Mar;10(2):99-107
12579034
Microcirculation. 2004 Mar;11(2):179-93
15280091
J Clin Invest. 2004 Oct;114(8):1136-45
15489961
Arch Intern Med. 1981 Jun;141(7):891-3
7235808
J Clin Epidemiol. 1992 Aug;45(8):893-909
1624972
Am J Med Sci. 1993 Mar;305(3):150-6
8447334
Am J Med. 1997 Feb;102(2):171-7
9217567
J Am Soc Nephrol. 1999 Jan;10(1):187-92
9890326
West Afr J Med. 1999 Apr-Jun;18(2):114-8
10504868
N Engl J Med. 2004 Feb 26;350(9):886-95
14985486